

CCL18 (Human) ELISA Kit

Catalog Number KA1757

96 assays

Version: 02

Intended for research use only



Table of Contents

| Introduction | 3 |
|-------------------------------------|----|
| Principle of the Assay | 3 |
| General Information | 4 |
| Materials Supplied | 4 |
| Storage Instruction | 4 |
| Materials Required but Not Supplied | 4 |
| Assay Protocol | 5 |
| Reagent Preparation | 5 |
| Assay Procedure | 6 |
| Data Analysis | 7 |
| Calculation of Results | 7 |
| Performance Characteristics | 7 |
| Resources | 9 |
| Troubleshooting | 9 |
| Plate Layout | 11 |



Introduction

Principle of the Assay

PARC (Pulmonary and activation-regulated chemokine) belongs to the CC-Chemokines. PARC is referred to also as AMAC-1 (alternative activated macrophage associated CC-Chemokine), MIP-4 (macrophage inflammatory protein-4), or DC-CK1 (dendritic cell-derived chemokine-1). PARC is chemotactic for both activated CD3 (+) T-cells and non-activated CD14 (-) lymphocytes, but not for monocytes or granulocytes.

The CCL18 (Human) ELISA Kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human PARC in serum, plasma, cell culture supernatants and urine. This assay employs an antibody specific for human PARC coated on a 96-well plate. Standards and samples are pipetted into the wells and PARC present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-human PARC antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of PARC bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.



General Information

Materials Supplied

| Component | Amount | | |
|---|--------------------------------|--|--|
| PARC Microplate (Item A): Coated with anti-human PARC | 96 wells (12 strips x 8 wells) | | |
| Wash Buffer Concentrate (20x) (Item B) | 25 ml | | |
| Standards: Recombinant human PARC (Item C) | 2 vials | | |
| Assay Diluent A (Item D): 0.09% sodium azide as preservative. For | 00 | | |
| Standard/Sample (serum/plasma) diluent. | 30 ml | | |
| Assay Diluent B (Item E): 5x concentrated buffer. For Standard/Sample | 15 ml | | |
| (cell culture medium/urine) dilunt. | | | |
| Detection Antibody PARC (Item F): Biotinylated anti- human PARC (each | 2 vials | | |
| vial is enough to assay half microplate). | | | |
| HRP-Streptavidin concentrate (Item G): 600x concentrated | 200 μΙ | | |
| HRP-conjugated Streptavidin. | | | |
| TMB One-Step Substrate Reagent (Item H): 3, 3', 5, 5'- | 12 ml | | |
| tetramethylbenzidine (TMB) in buffered solution. | | | |
| Stop Solution (Item I): 0.2 M sulfuric acid. | 8 ml | | |

Storage Instruction

May be stored for up to 6 months at 2° to 8°C from the date of shipment. Standard (recombinant protein) should be stored at -20°C or -80°C (recommended at -80°C) after reconstitution. Opened Microplate Wells or reagents may be store for up to 1 month at 2° to 8°C. Return unused wells to the pouch containing desiccant pack, reseal along entire edge.

Note: the kit can be used within one year if the whole kit is stored at -20 °C. Avoid repeated freeze-thaw cycles.

Materials Required but Not Supplied

- 1. Microplate reader capable of measuring absorbance at 450 nm.
- 2. Precision pipettes to deliver 2 µl to 1 ml volumes.
- 3. Adjustable 1-25 ml pipettes for reagent preparation.
- 4. 100 ml and 1 liter graduated cylinders.
- 5. Absorbent paper.
- 6. Distilled or deionized water.
- 7. Log-log graph paper or computer and software for ELISA data analysis.
- 8. Tubes to prepare standard or sample dilutions.




Assay Protocol

Reagent Preparation

- 1. Bring all reagents and samples to room temperature (18 25 ℃) before use.
- 2. Sample dilution: If your samples need to be diluted, Assay Diluent A (Item D) is used for dilution of serum/plasma samples. 1x Assay Diluent B (Item E) should be used for dilution of culture supernatants and urine.
 - Suggested dilution for normal serum/plasma: 200-2,000 fold*.
 - *Please note that levels of the target protein may vary between different specimens. Optimal dilution factors for each sample must be determined by the investigator.
- 3. Assay Diluent B should be diluted 5-fold with deionized or distilled water.
- 4. Preparation of standard: Briefly spin the vial of Item C. Add 700 μl Assay Diluent A (for serum/plasma samples) or 1x Assay Diluent B (for cell culture medium/urine samples) into Item C vial to prepare a 50 ng/ml standard. Dissolve the powder thoroughly by a gentle mix. Add 40 μl PARC standard from the vial of Item C, into a tube with 960 μl Assay Diluent A or 1x Assay Diluent B to prepare a 2000 pg/ml stock standard solution. Pipette 400 μl Assay Diluent A or 1x Assay Diluent B into each tube. Use the stock standard solution to produce a dilution series (shown below). Mix each tube thoroughly before the next transfer. Assay Diluent A or 1x Assay Diluent B serves as the zero standard (0 pg/ml).

40 µl standard



- 5. If the Wash Concentrate (20x) (Item B) contains visible crystals, warm to room temperature and mix gently until dissolved. Dilute 20 ml of Wash Buffer Concentrate into deionized or distilled water to yield 400 ml of 1x Wash Buffer.
- 6. Briefly spin the Detection Antibody vial (Item F) before use. Add 100 μl of 1x Assay Diluent B into the vial to prepare a detection antibody concentrate. Pipette up and down to mix gently (the concentrate can be stored at 4°C for 5 days). The detection antibody concentrate should be diluted 100-fold with 1x Assay Diluent B and used in step 4 of Part VI Assay Procedure.



7. Briefly spin the HRP-Streptavidin concentrate vial (Item G) and pipette up and down to mix gently before use. HRP-Streptavidin concentrate should be diluted 600-fold with 1x Assay Diluent B.

For example: Briefly spin the vial (Item G) and pipette up and down to mix gently. Add 20 µl of HRP-Streptavidin concentrate into a tube with 12 ml 1x Assay Diluent B to prepare a 600-fold diluted HRP-Streptavidin solution (don't store the diluted solution for next day use). Mix well.

Assay Procedure

- 1. Bring all reagents and samples to room temperature (18 25 °C) before use. It is recommended that all standards and samples be run at least in duplicate.
- 2. Add 100 μl of each standard (see Reagent Preparation step 2) and sample into appropriate wells. Cover well and incubate for 2.5 hours at room temperature or overnight at 4 °C with gentle shaking.
- 3. Discard the solution and wash 4 times with 1x Wash Solution. Wash by filling each well with Wash Buffer (300 µl) using a multi-channel Pipette or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
- 4. Add 100 μl of 1x prepared biotinylated antibody (Reagent Preparation step 6) to each well. Incubate for 1 hour at room temperature with gentle shaking.
- 5. Discard the solution. Repeat the wash as in step 3.
- Add 100 μl of prepared Streptavidin solution (see Reagent Preparation step 7) to each well. Incubate for 45 minutes at room temperature with gentle shaking.
- 7. Discard the solution. Repeat the wash as in step 3.
- 8. Add 100 μl of TMB One-Step Substrate Reagent (Item H) to each well. Incubate for 30 minutes at room temperature in the dark with gentle shaking.
- 9. Add 50 µl of Stop Solution (Item I) to each well. Read at 450 nm immediately

Summary

- 1. Prepare all reagents, samples and standards as instructed.
- 2. Add 100 µl standard or sample to each well. Incubate 2.5 hours at room temperature or over night at 4 °C.
- 3. Add 100 µl prepared biotin antibody to each well. Incubate 1 hour at room temperature.
- 4. Add 100 µl prepared Streptavidin solution. Incubate 45 minutes at room temperature.
- 5. Add 100 µl TMB One-Step Substrate Reagent to each well. Incubate 30 minutes at room temperature.
- 6. Add 50 µl Stop Solution to each well. Read at 450 nm immediately.




Data Analysis


Calculation of Results

Calculate the mean absorbance for each set of duplicate standards, controls and samples, and subtract the average zero standard optical density. Plot the standard curve on log-log graph paper or using Sigma plot software, with standard concentration on the x-axis and absorbance on the y-axis. Draw the best-fit straight line through the standard points.

Typical Data

These standard curves are for demonstration only. A standard curve must be run with each assay.





Performance Characteristics

Sensitivity

The minimum detectable dose of PARC is typically less than 2 pg/ml

Recovery

Recovery was determined by spiking various levels of human PARC into human serum, plasma and cell culture media. Mean recoveries are as follows:

| Sample Type | Average % Recovery | Range (%) | |
|--------------------|--------------------|-----------|--|
| Serum | 95.74 | 83-103 | |
| Plasma | 96.53 | 84-104 | |
| Cell culture media | 98.61 | 86-105 | |



Linearity

| Sample Type | | Serum | Plasma | Cell Culture Media |
|-------------|-----------------------|--------|--------|--------------------|
| 1:2 | Average % of Expected | 94 | 95 | 96 |
| | Range (%) | 83-103 | 84-104 | 85-104 |
| 1:4 | Average % of Expected | 97 | 97 | 96 |
| | Range (%) | 85-104 | 84-103 | 83-103 |

Reproducibility

Intra-Assay: CV<10% Inter-Assay: CV<12%

Specificity

Cross Reactivity: This ELISA kit shows no cross-reactivity with any of the cytokines tested (e.g., human Angiogenin, BDNF, BLC, ENA-78, FGF-4, IL-1 α , IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 p70, IL-12 p40, IL-13, IL-15, IL-309, IP-10, G-CSF, GM-CSF, IFN- γ , Leptin (OB), MCP-1, MCP-2, MCP-3, MDC, MIP-1 α , MIP-1 β , MIP-1 δ , PDGF, RANTES, SCF, TARC, TGF- β , TIMP-1, TIMP-2, TNF- α , TNF- β , TPO, VEGF).



Resources

Troubleshooting

| Problem | Cause | Solution | | | |
|---------------------|-----------------------------------|---|--|--|--|
| Poor standard curve | Inaccurate pipetting | Check pipettes | | | |
| | Improper standard dilution | Ensure briefly spin the vial of Item C and | | | |
| | | dissolve the powder thoroughly by a gentle | | | |
| | | mix. | | | |
| Low signal | Too brief incubation times | Ensure sufficient incubation time; assay | | | |
| | | procdure step 2 change to over night | | | |
| | Inadequate reagent volumes or | Check pipettes and ensure correct | | | |
| | improper dilution | preparation | | | |
| Large CV | Inaccurate pipetting | Check pipettes | | | |
| High background | Plate is insufficiently washed | Review the manual for proper wash. If using a | | | |
| | | plate washer, check that all ports are | | | |
| | | unobstructed. | | | |
| | Contaminated wash buffer | Make fresh wash buffer | | | |
| Low sensitivity | Improper storage of the ELISA kit | Store your standard at < -20℃ after | | | |
| | | reconstitution, others at 4℃. Keep substrate | | | |
| | | solution protected from light | | | |
| | Stop solution | Stop solution should be added to each well | | | |
| | | before measure | | | |



Reference

- 1. Hieshima K et al A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. Journal of Immunology 159 (3): 1140-1149 (1997).
- 2. Reape TJ et al Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques. American Journal of Pathology 154 (2): 365-74 (1999).



Plate Layout

| 12 | | | | | | | | |
|----|---|---|---|---|---|---|---|---|
| , | | | | | | | | |
| 11 | | | | | | | | |
| ' | | | | | | | | |
| 10 | | | | | | | | |
| | | | | | | | | |
| 6 | | | | | | | | |
| | | | | | | | | |
| 8 | | | | | | | | |
| | | | | | | | | |
| 7 | | | | | | | | |
| | | | | | | | | |
| 9 | | | | | | | | |
| | | | | | | | | |
| 5 | | | | | | | | |
| | | | | | | | | |
| 4 | | | | | | | | |
| | | | | | | | | |
| င | | | | | | | | |
| | | | | | | | | |
| 7 | | | | | | | | |
| | | | | | | | | |
| - | | | | | | | | |
| | ٧ | В | ပ | ۵ | Ш | Щ | g | エ |